scission under different pH conditions to afford the corresponding cyano-oximes 3b-14b, and the oxidation of selected cyano-oximes to the nitro derivatives 3c-10c, 12c, 14c (Scheme 1).
The ionization behaviour of the newly synthesised products as well as the results of their preliminary pharmacological characterisation as inhibitors of rat DHODH are also discussed.
A molecular modelling investigation was carried out to shed light on the biological activity profile obtained from in vitro assays.
Chemistry
The synthetic pathway used to prepare the products described in the present work is reported in Scheme 1. The N-substituted furazancarboxamides 3a-14a were obtained by direct coupling in tetrahydrofuran (THF) solution of furazancarboxylic acid 2 with the appropriate anilines 3-14 in the presence of dichloro(triphenyl)phosphorane (Ph 3 PCl 2 ). These compounds were converted into the corresponding oximes 3b-14b by treatment with NaOH in methanol solution. KMnO 4 oxidation in acetone/water of a number of oxime derivatives afforded the nitro compounds 3c-10c, 12c, 14c. 1 H and 13 C-NMR spectra are in keeping with the proposed structures. In particular, we assigned the E configuration to the oxime compounds on the basis of their 13 C-NMR spectra; for all these products the 13 CN chemical shifts fell in the very narrow range 108.6-109.6 ppm (DMSO-d 6 ). A similar chemical shift (109.66 ppm) was measured, in the same solvent, for the 13 CN group of the E-2-cyano-2-isonitroso-Nmorpholinylacetamide (A, Figure 2 ) [11] . When A was heated at 100 °C in DMSO-d 6, it underwent partial conversion into its Z-stereoisomer (B, Figure 2 ), which showed the 13 CN resonance at 113.66 ppm. This is in keeping with the known shielding effect exerted by the oxime OH that induces an upfield shift on the adjacent carbon (steric compression shift) [12] .
All the attempts to obtain thermal isomerization under the same conditions of cyano-oximes described in the present work failed. A similar behaviour had already been observed for some carbamoyl-substituted cyano-oximes [13] . Also the preparation of the oxime derivatives 3b-14b by action of isopentylnitrite on the corresponding sodium salts of 2-cyano-Nphenylacetamides afforded only the E forms. A theoretical DFT study was carried out to compute the relative thermodynamic stabilities of E and Z isomers for compounds 3b, 10b, 14b, which confirmed that the E isomer is consistently about 3.7 kcal mol -1 more stable (Table 1 ). For compound 3b the minimum energy reaction path for the E-Z isomerisation was computed as previously described [14] , finding an activation energy of 52.7 kcal mol -1 (Figure 3 ), which is in excellent accordance with the one reported for (hydroxyimino)propanedinitrile (54.9 kcal mol -1 ) [14] . Both the greater thermodynamic stability of the E isomer and the high energy barrier make isomerisation not viable under the experimental conditions described above.
X-ray diffraction
An X-ray diffraction study confirmed the assigned E configuration for compounds 6b, 8b ( Figure 4 ). Both molecules deviate from planarity and the phenyl ring is rotated around C(1)-N(1) by 17° in 6b and by 23° in 8b with respect to the nearly planar part of the molecule. The figure shows the E configuration with respect to the C(8)-N(2) double bond (1.277(6) and 1.279(1) Å for 6b and 8b respectively). All the C-N bond distances are in agreement with the values reported in literature for analogous bonds [15] . Also the C-C and C-O bond distances agree with literature values. The packing diagram of both structures shows two types of intermolecular hydrogen bonds: H(1)···N(3) (2.41-2.57 Å) and H(2)···O(1) (1.83 Å average).
Kinetics of furazan ring opening
Kinetics of ring scission (Scheme 2) of furazancarboxamides 3a-14a were assessed in buffered solution at physiological pH (7.4) at 37 °C by monitoring the disappearance of compounds by reversed-phase high-performance liquid chromatography (RP-HPLC). The ring opening strictly followed first order kinetics. The measured half-lives (t 1/2 ) fall in the range 69.0-123.4 min; all values are reported in Table 2 , together with the data found for leflunomide 1, taken as reference. After 24-h incubation under the same conditions, only 20% of 1a was formed from 1. The most stable product was the phenyl substituted term 11a, and the less stable the 4-nitrophenyl derivative 10a. The behaviour of leflunomide and its strict analogue 3a was also studied at pH 1 and 10. After 6 h both compounds were unaltered in acidic medium, while in basic conditions ring opening was strongly accelerated (t 1/2 < 1 min and t 1/2 = 70 min for 3a and leflunomide 1, respectively). This picture is in keeping with the knowledge that the furazan system undergoes base-induced ring scission much faster than the isoxazole ring [9] .
Dissociation constants
Potentiometric titrations of the oxime compounds 3b-14b were carried out with a Sirius GLpK a automated potentiometric system. The titrations were performed in water using methanol in different ratios as co-solvent. The aqueous pK a s (Table 3) were determined by extrapolation to 0% methanol, according to the Yasuda-Shedlovsky procedure [16] . All the oximes behave as quite strong acids in accordance with the presence of two electron withdrawing groups on the hydroxyimino moiety. Their pK a values fall in the range 4.61-5.12, the most acidic product being the 4-nitrophenyl substituted compound 10b, the least acidic the phenyl substituted term 11b. Consequently, as in the case of 1a, the ionised forms are largely predominant for all the products at physiological pH. The determination of dissociation constants of all nitro derivatives by potentiometric titration was prevented by their marked acidity.
Results and discussion
DHODH (EC 1.3.99.11) is a mitochondrial protein involved in de novo pyrimidine biosynthesis. It catalyses the ubiquinone-mediated oxidation of dihydroorotate (DHO) to orotate [17] . DHODH is considered as an important target for the development of immunomodulating agents. A771726 1a is a potent inhibitor of this enzyme. The Z configuration of 1a bears the enolic hydroxy group in cis position with respect to the amide moiety. The experimental binding mode of this configuration within the active site of human DHODH has been reported [18] . In particular, the 4-trifluoromethylphenyl moiety establishes several hydrophobic contacts with residues of the tunnel leading to active site. The enolic OH group interacts via hydrogen bonding with Tyr356, while the amide carbonyl is hydrogen bonded to Arg136 through a water molecule. SAR studies carried out on analogues of A771726 show that the most potent inhibitors contain a cyclopropyl residue at the 3-position of the 3-hydroxy propenamide scaffold, while larger substituents are detrimental to the activity. In addition, they bear at the 4-position of the phenyl ring small lipophilic groups, as well as weak hydrogen bond acceptors [19] . In view of the quick conversion at physiological pH of furazans 3a-14a into the related oxime derivatives 3b-14b, only these latter compounds and some of their nitro counterparts were assayed for their DHODH inhibitory potency on rat liver mithocondrial/microsomal membranes. A procedure adapted from literature was employed, in which oxidation of DHO to orotate is monitored following the concomitant reduction of the chromophore 2,6-dichlorophenolindophenol (DCIP) [20] ; the results are collected in Table 3 . Analysis of the data shows that most products are inactive when tested at 100 M. 4-Fluorophenyl and 3,5-difluorophenyl substituted compounds 6b and 9b at this concentration were able to trigger feeble inhibition of the enzyme, 27% and 23% respectively. Only the strict oxime analogue of A771726 3b was able to inhibit the enzyme in a concentration-dependent manner (IC 50 = 60 M), although much less effectively than the lead. The general very low inhibitory activity of these products could be ascribed to the E configuration of the oxime group, which prevents them from assuming the same binding mode of the lead in the active cleft of the enzyme. Also the nitro substituted compounds 3c-10c, 12c, 14c are not potent inhibitors, but overall more effective than the corresponding oximes. The most potent product was 3c, the strict analogue of A771726, followed by the 4-phenyl and 4-nitro substituted products 14c and 10c, respectively. All the other terms of the series inhibited the activity of the enzyme only to the extent of 20-29%, when tested at 100 M. Docking of the most active compounds into the active site of DHODH confirmed the inability of oximes to hydrogen bond to Tyr356 due to their inappropriate stereochemistry ( Figure 5a ). While nitro compounds have the correct geometry to interact productively with Tyr356, on one side the charge-enhanced hydrogen bond is not as strong as for the leflunomide metabolite 1a since the negative charge is spread on two oxygen atoms instead of being mostly localized on the enolic oxygen. On the other side, the other negatively charged oxygen does not interact as effectively as leflunomide's methyl group with the lipophilic pocket delimited by Val134, Val143 and the two methyl groups of flavin mononucleotide (FMN) ( Figure 5b ). These considerations provide a rationale for the lower activity of the newly synthesised analogues compared to the lead. Both the human DHODH in complex with leflunomide [18] and rat DHODH in complex with brequinar [21] were used as docking targets obtaining the same results, proving that the small differences in terms of primary and tertiary structure between the two isozymes do not influence the binding mode of the compounds object of this work.
Conclusions
A series of furazan analogues of leflunomide have been realised (3a-14a). These compounds are readily converted at physiological pH into their oxime counterparts (3b-14b). The latter have been assayed as DHODH inhibitors; their low potency is probably due to the unfavourable stereochemistry of the oxime substructure, which cannot effectively mimic the enolate moiety of A771726. Oxidation of the oxime group to nitro improved the activity on DHODH, putting into evidence the importance of a properly oriented charge-enhanced hydrogen bond acceptor. Further efforts are ongoing to obtain more potent leflunomide bioisosters.
Experimental protocols

Chemistry
Melting points were determined on a Büchi 530 apparatus. The compounds were routinely checked by IR spectroscopy (Shimadzu, FT-IR 8101 M) and mass spectrometry (Finnigan-Mat TSQ-700 spectrometer, 70 eV, direct inlet). 1 Compounds 1 [22] , 1a [22] and 2 [23] were synthesized according to literature methods.
Elemental analyses of the new compounds are within 0.4% of the theoretical values and are reported in the Supplementary Material. In case of compounds 3c, 5c and 9c, that showed elemental analyses slightly out of the commonly accepted range, the purity was also assessed by RP-HPLC (> 99 %). Analyses were performed on a HP1100 chromatograph system (Agilent Technologies, Palo Alto, CA, USA) equipped with an injector (Rheodyne, Cotati, CA, USA), a quaternary pump (model G1311A), a membrane degasser (model G1379A), and a diode-array detector (DAD, model G1315B) integrated in the HP1100 system. Data analysis was performed using a HP ChemStation system (Agilent Technologies). The analytical column was a Nucleosil 100-5C18 Nautilus (2504.6 mm, 5 mm particle size) (Macherey-Nagel). Compounds were dissolved in CH 3 CN and injected through a 20 L loop.
The mobile phase consisted of CH 3 CN/water with 0.1% trifluoroacetic acid (ranging from 60/40 to 80/20 ratio, according to the retention factor of the compounds). HPLC retention times (t R ) were obtained at flow rates of 1.2 mL min -1 , and the column effluent was monitored at 210 and 270 nm referenced against 360 nm.
Furazancarboxamide derivatives: general synthetic procedure
To a stirred solution of furazancarboxylic acid 2 (2.6 mmol) and the appropriate aniline 3-14
(2.6 mmol) in dry THF (25 mL) Ph 3 PCl 2 (5.46 mmol, 2.1 eq) was added portionwise under an inert atmosphere. The resulting suspension was stirred for 2 h, then poured into chilled 2 M HCl (50 mL). The mixture was extracted exhaustively with Et 2 O, then the collected organic layers were dried and concentrated under reduced pressure. The residue was purified by flash chromatography obtaining the title compound. 
2-Hydroxyiminopropionitrile derivatives: general synthetic procedure
1 M NaOH (4.2 mmol, 4.2 mL) was added to an ice cooled solution of the amide 3a-13a (1 mmol) in MeOH (11 mL). The mixture was stirred at room temperature for 2 h, then diluted with water (5 mL). The pH of the mixture was adjusted to 1 by addition of 6 M HCl. The resulting suspension was exhaustively extracted with Et 2 O. The organic layers were collected, dried and concentrated under reduced pressure to afford the pure title compound. 
2-Hydroxyimino-3-oxo-3-[4-(trifluoromethyl)phenyl]aminopropionitrile (3b)
2-Hydroxyimino-3-oxo-3-(biphenyl-4-yl)aminopropionitrile (14b)
Yellow solid; yield 80%; m.p. 250-251 °C (from toluene); 1 
2-Nitropropionitrile derivatives: general procedure
KMnO 4 (1.5 mmol, 237 mg) was added portionwise to an ice-cooled solution of the oxime (1.0 mmol) in acetone/water (1:2 v/v; 20 mL). The mixture was stirred at room temperature for 24 h, then filtered under Celite. The filtrate was acidified to pH 3 by adding glacial CH 3 COOH, then washed with Et 2 O (220 mL), and concentrated under reduced pressure.
The resulting solid was triturated with isopropyl ether obtaining the title compound as potassium salt. Anal. (C 15 H 10 N 3 O 3 K) C, H, N.
2-Nitro-3-oxo-3-[(4-trifluoromethyl)phenyl]aminopropionitrile potassium salt (3c)
3-[3,5-Bis(trifluoromethyl)phenyl]amino-2-nitro-3-oxopropionitrile potassium salt
3-(4-Fluorophenyl)amino-2-nitro-3-oxopropionitrile potassium salt (6c)
3-(3-Fluorophenyl)amino-2-nitro-3-oxopropionitrile potassium salt (7c)
2-Nitro-3-(4-nitrophenyl)amino-3-oxopropionitrile potassium salt (10c)
X-ray structure determination of 6b and 8b
Crystal and refinement data are reported in Table 4 . The reflection data, using a crystal obtained from toluene solution, have been collected on a Gemini R Ultra diffractometer [25] .
The hydrogen atom coordinates have been calculated (6b) or found (8b) and refined with U iso set at 1.5 times U eq of the corresponding atom (6b) or with U iso free (8b). All other atoms have been anisotropically refined. Programs used were CrysAlisPro [25] for data collection and correction and SHELXTL [26] for structure solution, refinement and molecular graphics.
No absorption correction has been made. CIF files have been deposited at the Cambridge Crystallographic Data Centre as CCDC 784463 for 6b and CCDC 784464 for 8b; bond length and angles are reported in the Supplementary Material.
Evaluation of stability in aqueous buffer solutions
A solution of each compound (10 mM) in methanol was added to phosphate buffer (pH 7.4, 50 mM) preheated at 37 °C. To carry out the assay at pH 1 and pH 10, 0.1 M HCl and 0.1 M phosphate buffer were used, respectively. The final concentration of the compound was 100 M. The resulting solution was maintained at 37.0 ± 0.5 °C, and at 30-min time intervals the reaction mixture was analyzed by RP-HPLC. Incubations were conducted in triplicate. The RP-HPLC procedure allowed the separation and quantitation of the unchanged compound and newly formed oxime derivatives. HPLC analyses were performed with the HP1100 chromatograph system previously described. The analytical column was a Zorbax Eclipse XDB-C8 (Agilent, 1504.6 mm, 5 m particle size). The mobile phase consisted of methanol/water with 0.1% trifluoroacetic acid (ranging from 60/40 to 75/25 ratio, according to the retention factor of the compounds); flow rate and injection volume were 1.2 mL min -1 and 20 L, respectively. The column effluent was monitored at 230 and 270 nm referenced against a 360 nm wavelength. Quantitation was performed by comparison of peak areas with standards chromatographed under the same conditions. The percentage of unchanged compound versus time was fitted with a one-phase exponential decay equation using GraphPad Prism version 5 to obtain k obs ; t 1/2 was calculated from equation 1:
Dissociation constant determination
Potentiometric titrations were performed using the GLpK a apparatus (Sirius Analytical The initial estimates of the p s K a values (the apparent ionization constants in the watermethanol mixtures) were obtained and aqueous pK a values were determined by extrapolation to zero content of cosolvent according to the Yasuda-Shedlovsky procedure [16] . All titrations were performed under N 2 at 25.0 ± 0.1 °C.
Biological evaluation
Preparation of rat liver membranes
Crude mitochondrial/microsomal membranes from livers of male Wistar rats (200-250 g)
were prepared by homogenisation and differential centrifugation [20, 27] . Homogenisation buffer was 25 mM sodium phosphate, 250 mM sucrose and 0.3% v/v Protease Inhibitor Cocktail for use with mammalian cell and tissue extracts (SIGMA Catalog Number: P8340) at pH 7.4. The homogenate (9 mL homogenisation buffer/g wet tissue) was centrifuged at 470g for 10 min, the supernatant retained, and the pellets re-homogenised in buffer (4.5 mL/g wet tissue). This homogenate was centrifuged (470g, 10 min) and the supernatant was combined with the one obtained earlier and centrifuged (50000g, 60 min). The membranes were washed by resuspension in homogenisation buffer plus 150 mM NaCl, 1 mM EDTA and 1 mM EGTA before final centrifugation (50000g, 60 min) and re-suspension in the homogenisation buffer (2 mL/g wet tissue). All of the above steps were performed at 4 °C and aliquots of the final membrane preparation were stored at -80 °C.
Dihydroorotate dehydrogenase assay
Inhibition of rat liver DHODH activity by tested compounds was assessed using a DCIP- 
where [I] is the inhibitor concentration.
Michaelis-Menten constant (K m ) for DHO, determined by the usual procedure, was found to be 14.6 M, in keeping with previous work [28] .
Molecular modelling
The molecular models of compounds 3b, 3c, 10b, 10c, 14b, 14c and orotate were built using standard bond lengths and angles with the MOE software suite [29] . In accordance with their pK a values (Table 3) the SANDER module of the AMBER 10 software package [32] , while harmonically restraining heavy atoms to the initial crystallographic coordinates with a force constant of 1000 kcal mol -1 Å -2 . AMBER FF99 parameters were assigned to protein atoms and GAFF parameters to the co-crystallized inhibitor and orotate, while atom-centred point charges were fitted to the quantum-mechanical electrostatic potential according to the RESP method [33] .
Equilibrium internal coordinates, force-field parameters and electrostatic charges for the FMN cofactor were taken from literature [34] . After removing the co-crystallized inhibitor, docking of compounds 3b, 3c, 10b, 10c, 14b, 14c was carried out using AutoDock 4.0.1 [35] [36] [37] . A grid with a 0.375 Å step size was centred on the inhibitor binding site and energy maps were pre-computed with AutoGrid, then flexible docking was carried out with AutoDock. The target proteins were kept rigid, while ligands were left free to explore the conformational space inside the enzyme cavity; 200 separate docking simulations were run on each target using the Lamarckian genetic algorithm with default parameters. Frequency calculations were performed at the same level of theory as the geometry optimizations to obtain zero-point energies (no scaling) and to characterize the stationary points as local minima, or as a first-order saddle point for the transition state structure in the isomerisation of 3b. to 58 (%Wt); the extrapolation to zero was obtained by the Yasuda-Shedlovsky procedure [16] .
Figure captions
b Enzyme activity was measured by DCIP reduction assay and IC 50 values were calculated with non-linear regression analysis. 
